Product image of Natriumrisedronaat Sandoz (Risedronate Sodium) supplied by GNH India

Natriumrisedronaat Sandoz

Active Ingredient:
Risedronate Sodium
Origin:
EU

Natriumrisedronaat Sandoz (Risedronate Sodium)

Risedronate Sodium, the active ingredient in Natriumrisedronaat Sandoz, is a bisphosphonate presented as an oral dosage form for oral use. It is indicated for the treatment of osteoporosis and Paget’s disease of bone in various patient groups.
GNH India supplies Natriumrisedronaat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Natriumrisedronaat Sandoz is a bisphosphonate used to manage conditions involving abnormal bone turnover.

  • Osteoporosis in postmenopausal women: reduces risk of vertebral and non‑vertebral fractures.
  • Osteoporosis in men: improves bone mineral density and lowers fracture incidence.
  • Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss.
  • Paget's disease of bone: normalises bone remodeling and alleviates pain.

How It Works

  • Risedronate Sodium binds to hydroxyapatite at sites of active bone remodeling, where it is taken up by osteoclasts. By inhibiting the enzyme farnesyl pyrophosphate synthase, it disrupts the prenylation of small GTP‑binding proteins, leading to reduced osteoclast activity and decreased bone resorption.

Side Effects

Risedronate Sodium may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Abdominal pain: cramping or discomfort.
  • Dyspepsia: indigestion or heartburn.
  • Constipation: reduced bowel movements.
  • Musculoskeletal pain: aches in joints or muscles.
  • Diarrhoea: loose stools.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone in the oral cavity.
  • Atypical femur fracture: unusual break in the thigh bone.
  • Severe esophageal ulceration: painful inflammation of the esophagus.
  • Acute renal impairment: sudden decline in kidney function.
  • Hypocalcaemia: low blood calcium levels.
  • Anaphylactic reaction: severe allergic response.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

  • Renal function assessment: ensure adequate kidney function before prescribing.
  • Calcium and vitamin D status: verify sufficient intake to support bone health.
  • Concomitant gastrointestinal disease: avoid in patients with active esophageal disorders.
  • Dental procedures: advise dental evaluation before starting treatment to reduce jaw osteonecrosis risk.
  • Drug administration timing: take with a full glass of water on an empty stomach, remaining upright for at least 30 minutes.

Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Risedronate Sodium can interact with several medicines, affecting absorption or increasing toxicity.

Major Interactions (Avoid)

  • Calcium supplements taken simultaneously: markedly reduces risedronate absorption.
  • Antacids containing aluminium or magnesium: interfere with drug uptake.
  • Concomitant use of other bisphosphonates: unnecessary duplication of effect.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal irritation.
  • Nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal impairment.
  • Vitamin D analogues: monitor calcium levels to avoid hypercalcaemia.

Frequently Asked Questions

Natriumrisedronaat Sandoz, containing risedronate sodium, is prescribed to treat osteoporosis in postmenopausal women, men and patients with glucocorticoid‑induced bone loss, as well as Paget’s disease of bone. It works by slowing bone resorption, helping to maintain bone strength and reduce fracture risk.

Risedronate sodium binds to hydroxyapatite at sites of active bone remodeling. When osteoclasts attempt to resorb bone, the drug is internalised and inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This disruption reduces osteoclast activity, decreasing bone breakdown and supporting bone density.

The specific dose and dosing schedule for Natriumrisedronaat Sandoz are determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for risedronate sodium in pregnancy and lactation are limited. The product should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Risedronate sodium belongs to the bisphosphonate class, which is widely used for its proven efficacy in reducing fracture risk. Compared with other bisphosphonates, it offers a similar mechanism of action but may differ in dosing frequency and tolerability profile. Clinicians choose the agent that best matches patient preferences and clinical circumstances.

Store Natriumrisedronaat Sandoz at temperatures below 25 °C in its original packaging. Protect the product from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during this period to optimise absorption.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe esophageal ulceration, acute renal impairment, and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Patients with severe renal impairment (e.g., creatinine clearance below the recommended threshold), active esophageal disorders, inability to remain upright after dosing, or known hypersensitivity to risedronate sodium or any excipients should avoid using this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Risedronate Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT